{"id":49239,"date":"2026-02-07T00:24:58","date_gmt":"2026-02-06T22:24:58","guid":{"rendered":"https:\/\/otpor.media\/?p=49239"},"modified":"2026-02-07T00:25:00","modified_gmt":"2026-02-06T22:25:00","slug":"nije-klinicko-ispitivanje-nego-lijecenje-ruski-institut-krece-s-prvom-primjenom-cjepiva-protiv-raka","status":"publish","type":"post","link":"https:\/\/otpor.media\/?p=49239","title":{"rendered":"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka"},"content":{"rendered":"\n

Prva osoba na svijetu koja \u0107e zapo\u010deti lije\u010denje ruskim cjepivom protiv raka bit \u0107e pacijentica iz Srbije Jovana Aleksi\u0107, koja boluje od melanoma \u2013 raka ko\u017ee s metastazama. Lije\u010denje bi trebalo po\u010deti uskoro, najkasnije u sljede\u0107ih mjesec ili dva.<\/p>\n\n\n\n

To je za Sputnik<\/a><\/strong> potvrdio voditelj Odjela za patologiju na Sveu\u010dili\u0161tu Se\u010denov u Moskvi, dr. Sergej Boljevi\u0107. Kazao je da su upravo danas u Herzenovu institutu (Moskovski istra\u017eiva\u010dki onkolo\u0161ki institut imena P. A. Hercena \u2013 podru\u017enica Federalne dr\u017eavne prora\u010dunske ustanove \u201eNMIC Radiologija\u201c Ministarstva zdravstva Rusije) on i tim koji radi na cjepivu dobili tu informaciju od vije\u0107a Instituta.<\/p>\n\n\n\n

Lije\u010denje po\u010dinje<\/h3>\n\n\n\n

\u201eDakle, ne radi se o klini\u010dkim ispitivanjima, nego o lije\u010denju! Cjepivo za nju po\u010det \u0107e se primjenjivati od ponedjeljka (sva cjepiva su personalizirana) u Institutu za epidemiologiju i mikrobiologiju \u2018Gamaleja\u2019. Ne bi trebalo dugo trajati, a odluka da prvi pacijent bude iz Srbije donesena je isklju\u010divo zbog dobrih odnosa sa Srbijom. Naravno, postoje i drugi pacijenti s kojima istodobno radimo, ali ovo \u0107e biti prva osoba na svijetu koja \u0107e na ovaj na\u010din zapo\u010deti lije\u010denje ovog oblika raka\u201c, rekao je dr. Boljevi\u0107.<\/p>\n\n\n\n

Kako obja\u0161njava, nakon toga slijede dogovori s drugim lije\u010dnicima iz tima i s pacijenticom o datumu dolaska.<\/p>\n\n\n\n

\u201eCjepivo je primjenjivo u bilo kojoj fazi raka i metastaza te se prakti\u010dki mo\u017ee koristiti kod svih oblika raka, ali ruska vlada zasad je odlu\u010dila raditi s melanomom i rakom plu\u0107a. Ve\u0107 imamo desetak pacijenata s kojima radimo. Imamo i druge pacijente, ne samo s melanomom, koji ulaze u dijagnosti\u010dki postupak. Kada dobijemo dopu\u0161tenje za rad s drugim vrstama karcinoma, primjerice rakom dojke, pacijenti koji ve\u0107 prolaze postupak bit \u0107e prvi koji \u0107e biti dovedeni ovdje na lije\u010denje cjepivom\u201c, navodi.<\/p>\n\n\n\n

Visokotehnolo\u0161ki proces<\/h3>\n\n\n\n

Boljevi\u0107 obja\u0161njava da se u postupku izrade cjepiva koristi i umjetna inteligencija te da \u0107e cijeli tim uklju\u010den u taj proces o radu na cjepivu govoriti na opse\u017enoj konferenciji po\u010detkom travnja u So\u010diju.<\/p>\n\n\n\n

\u201eAko sve bude kako treba, ve\u0107 \u0107emo imati klini\u010dki rezultat koji \u0107e sigurno biti dobar, ali vidjet \u0107emo u kojoj mjeri. Ne vjerujem da ne\u0107e biti rezultata i nadamo se izvrsnom ishodu. No budu\u0107i da smo prvi na svijetu, onda razumijete \u2013 tko je prvi, ne zna ba\u0161 sve. Mislim da \u0107emo imati izvrstan rezultat, ali to treba potvrditi\u201c, isti\u010de.<\/p>\n\n\n\n

Prema njegovim rije\u010dima, pacijenti iz Rusije, kao i iz Republike Srpske, lije\u010dit \u0107e se na teret zdravstvenog fonda, zbog \u010dega su procedure za njih ne\u0161to sporije.<\/p>\n\n\n\n

\u201eSa Srbijom i drugim zainteresiranim zemljama jo\u0161 nema dogovora o financiranju, ali se nadamo da \u0107e uskoro do\u0107i do promjena. Zasad pacijenti sami pla\u0107aju lije\u010denje, a iz Srbije nam pacijenti koji se procijene kao kandidati dolaze preko na\u0161ih profesora koji rade u bolnicama u Srbiji. Oni prvi preuzimaju slu\u010daj i \u0161alju nam dijagnozu, nakon \u010dega se obavljaju konzultacije s lije\u010dnicima u Rusiji koji su dio tima. Nama se potom prenosi daljnji tijek lije\u010denja. Napravimo analizu, zatim video-vezu, organizira se razgovor s pacijentom i nakon toga se donosi odluka mo\u017ee li pacijent do\u0107i\u201c, obja\u0161njava lije\u010dnik.<\/p>\n\n\n\n

Boljevi\u0107 ka\u017ee da se radi o vrlo slo\u017eenim tehnolo\u0161kim postupcima koji su skupi, ali i u\u010dinkoviti u gotovo 95 posto slu\u010dajeva.<\/p>\n\n\n\n

Kako cjepivo djeluje?<\/h3>\n\n\n\n

\u201eNetko tko se, primjerice, izlije\u010di od melanoma cjepivom, vi\u0161e ne mo\u017ee oboljeti od tog oblika raka. Pojednostavljeno re\u010deno, uzimamo podatke iz stanica oboljelog tkiva, analiziramo ih i pronalazimo lijek. Dakle, postoji za\u0161tita za koju kasnije \u2018treniramo\u2019 na\u0161e stanice \u2013 dajemo im informacije o tome kako se boriti protiv raka. Ne protiv normalnih stanica, nego isklju\u010divo protiv stanica raka. Kad dobiju te informacije, znaju kako se boriti\u201c, poja\u0161njava.<\/p>\n\n\n\n

Boljevi\u0107 napominje da, ako se pacijent prehladi ili iz nekog drugog razloga u tom trenutku ne mo\u017ee primiti cjepivo, slijedi pauza od mjesec ili dva, nakon \u010dega se cijepljenje nastavlja.<\/p>\n\n\n\n

\u201ePacijenti bi trebali primiti ukupno deset doza cjepiva, koje se daje svaka dva tjedna, a nakon dvije ili tri doze mo\u017ee se vidjeti povla\u010di li se tumor i je li lije\u010denje u\u010dinkovito\u201c, ka\u017ee.<\/p>\n\n\n\n

Prema Boljevi\u0107evim rije\u010dima, cjepivo \u0107e se u po\u010detku primjenjivati na pacijentima koji su ve\u0107 iscrpili sve druge vrste lije\u010denja bez rezultata, kako bi se dokazala njegova u\u010dinkovitost.<\/p>\n\n\n\n

OTPOR.Media<\/sup><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Prva osoba na svijetu koja \u0107e zapo\u010deti lije\u010denje ruskim cjepivom protiv raka bit \u0107e pacijentica iz Srbije Jovana Aleksi\u0107, koja boluje od melanoma \u2013 raka ko\u017ee s metastazama. Lije\u010denje bi trebalo po\u010deti uskoro, najkasnije u sljede\u0107ih mjesec ili dva. To je za Sputnik potvrdio voditelj Odjela za patologiju na Sveu\u010dili\u0161tu Se\u010denov u Moskvi, dr. Sergej […]<\/p>\n","protected":false},"author":1,"featured_media":11641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"iawp_total_views":34,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[31],"tags":[],"class_list":["post-49239","post","type-post","status-publish","format-standard","has-post-thumbnail","category-zdravlje"],"yoast_head":"\nNije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka - OTPOR.Media<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/otpor.media\/?p=49239\" \/>\n<meta property=\"og:locale\" content=\"hr_HR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka\" \/>\n<meta property=\"og:description\" content=\"Prva osoba na svijetu koja \u0107e zapo\u010deti lije\u010denje ruskim cjepivom protiv raka bit \u0107e pacijentica iz Srbije Jovana Aleksi\u0107, koja boluje od melanoma \u2013 raka ko\u017ee s metastazama. Lije\u010denje bi trebalo po\u010deti uskoro, najkasnije u sljede\u0107ih mjesec ili dva. To je za Sputnik potvrdio voditelj Odjela za patologiju na Sveu\u010dili\u0161tu Se\u010denov u Moskvi, dr. Sergej […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/otpor.media\/?p=49239\" \/>\n<meta property=\"og:site_name\" content=\"OTPOR.Media\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/otpor.media\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T22:24:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T22:25:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/otpor.media\/wp-content\/uploads\/2024\/07\/covid_cijepljenje_18622.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1140\" \/>\n\t<meta property=\"og:image:height\" content=\"760\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"otpormedia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisao\/la\" \/>\n\t<meta name=\"twitter:data1\" content=\"otpormedia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Procijenjeno vrijeme \u010ditanja\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239\"},\"author\":{\"name\":\"otpormedia\",\"@id\":\"https:\\\/\\\/otpor.media\\\/#\\\/schema\\\/person\\\/a274232a44e6bceb3b5681f0fe2474ab\"},\"headline\":\"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka\",\"datePublished\":\"2026-02-06T22:24:58+00:00\",\"dateModified\":\"2026-02-06T22:25:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239\"},\"wordCount\":770,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/otpor.media\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/covid_cijepljenje_18622.jpeg\",\"articleSection\":[\"ZDRAVLJE\"],\"inLanguage\":\"hr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/otpor.media\\\/?p=49239#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239\",\"url\":\"https:\\\/\\\/otpor.media\\\/?p=49239\",\"name\":\"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka - OTPOR.Media\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/otpor.media\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/covid_cijepljenje_18622.jpeg\",\"datePublished\":\"2026-02-06T22:24:58+00:00\",\"dateModified\":\"2026-02-06T22:25:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239#breadcrumb\"},\"inLanguage\":\"hr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/otpor.media\\\/?p=49239\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239#primaryimage\",\"url\":\"https:\\\/\\\/otpor.media\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/covid_cijepljenje_18622.jpeg\",\"contentUrl\":\"https:\\\/\\\/otpor.media\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/covid_cijepljenje_18622.jpeg\",\"width\":1140,\"height\":760},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/otpor.media\\\/?p=49239#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Po\u010detna stranica\",\"item\":\"https:\\\/\\\/otpor.media\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/otpor.media\\\/#website\",\"url\":\"https:\\\/\\\/otpor.media\\\/\",\"name\":\"OTPOR.Media\",\"description\":\"Povratak u realnost\",\"publisher\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/otpor.media\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"hr\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/otpor.media\\\/#organization\",\"name\":\"OTPOR.Media\",\"url\":\"https:\\\/\\\/otpor.media\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\\\/\\\/otpor.media\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/otpor.media\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/logo-OTPOR-2026-1024x683.png\",\"contentUrl\":\"https:\\\/\\\/otpor.media\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/logo-OTPOR-2026-1024x683.png\",\"width\":1024,\"height\":683,\"caption\":\"OTPOR.Media\"},\"image\":{\"@id\":\"https:\\\/\\\/otpor.media\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/otpor.media\",\"https:\\\/\\\/www.youtube.com\\\/@milimarusic1\",\"https:\\\/\\\/www.tiktok.com\\\/@otpor.media\"],\"email\":\"otpormedia@gmail.com\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/otpor.media\\\/#\\\/schema\\\/person\\\/a274232a44e6bceb3b5681f0fe2474ab\",\"name\":\"otpormedia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/45a679ede28b0f3d33af0c73504f366135a2d7b98929bf9c49d873909aaac267?s=96&d=wavatar&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/45a679ede28b0f3d33af0c73504f366135a2d7b98929bf9c49d873909aaac267?s=96&d=wavatar&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/45a679ede28b0f3d33af0c73504f366135a2d7b98929bf9c49d873909aaac267?s=96&d=wavatar&r=g\",\"caption\":\"otpormedia\"},\"sameAs\":[\"https:\\\/\\\/test.otpor.media\"],\"url\":\"https:\\\/\\\/otpor.media\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka - OTPOR.Media","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/otpor.media\/?p=49239","og_locale":"hr_HR","og_type":"article","og_title":"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka","og_description":"Prva osoba na svijetu koja \u0107e zapo\u010deti lije\u010denje ruskim cjepivom protiv raka bit \u0107e pacijentica iz Srbije Jovana Aleksi\u0107, koja boluje od melanoma \u2013 raka ko\u017ee s metastazama. Lije\u010denje bi trebalo po\u010deti uskoro, najkasnije u sljede\u0107ih mjesec ili dva. To je za Sputnik potvrdio voditelj Odjela za patologiju na Sveu\u010dili\u0161tu Se\u010denov u Moskvi, dr. Sergej […]","og_url":"https:\/\/otpor.media\/?p=49239","og_site_name":"OTPOR.Media","article_publisher":"https:\/\/www.facebook.com\/otpor.media","article_published_time":"2026-02-06T22:24:58+00:00","article_modified_time":"2026-02-06T22:25:00+00:00","og_image":[{"width":1140,"height":760,"url":"https:\/\/otpor.media\/wp-content\/uploads\/2024\/07\/covid_cijepljenje_18622.jpeg","type":"image\/jpeg"}],"author":"otpormedia","twitter_card":"summary_large_image","twitter_misc":{"Napisao\/la":"otpormedia","Procijenjeno vrijeme \u010ditanja":"4 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/otpor.media\/?p=49239#article","isPartOf":{"@id":"https:\/\/otpor.media\/?p=49239"},"author":{"name":"otpormedia","@id":"https:\/\/otpor.media\/#\/schema\/person\/a274232a44e6bceb3b5681f0fe2474ab"},"headline":"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka","datePublished":"2026-02-06T22:24:58+00:00","dateModified":"2026-02-06T22:25:00+00:00","mainEntityOfPage":{"@id":"https:\/\/otpor.media\/?p=49239"},"wordCount":770,"commentCount":0,"publisher":{"@id":"https:\/\/otpor.media\/#organization"},"image":{"@id":"https:\/\/otpor.media\/?p=49239#primaryimage"},"thumbnailUrl":"https:\/\/otpor.media\/wp-content\/uploads\/2024\/07\/covid_cijepljenje_18622.jpeg","articleSection":["ZDRAVLJE"],"inLanguage":"hr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/otpor.media\/?p=49239#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/otpor.media\/#organization"}},{"@type":"WebPage","@id":"https:\/\/otpor.media\/?p=49239","url":"https:\/\/otpor.media\/?p=49239","name":"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka - OTPOR.Media","isPartOf":{"@id":"https:\/\/otpor.media\/#website"},"primaryImageOfPage":{"@id":"https:\/\/otpor.media\/?p=49239#primaryimage"},"image":{"@id":"https:\/\/otpor.media\/?p=49239#primaryimage"},"thumbnailUrl":"https:\/\/otpor.media\/wp-content\/uploads\/2024\/07\/covid_cijepljenje_18622.jpeg","datePublished":"2026-02-06T22:24:58+00:00","dateModified":"2026-02-06T22:25:00+00:00","breadcrumb":{"@id":"https:\/\/otpor.media\/?p=49239#breadcrumb"},"inLanguage":"hr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/otpor.media\/?p=49239"]}]},{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/otpor.media\/?p=49239#primaryimage","url":"https:\/\/otpor.media\/wp-content\/uploads\/2024\/07\/covid_cijepljenje_18622.jpeg","contentUrl":"https:\/\/otpor.media\/wp-content\/uploads\/2024\/07\/covid_cijepljenje_18622.jpeg","width":1140,"height":760},{"@type":"BreadcrumbList","@id":"https:\/\/otpor.media\/?p=49239#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Po\u010detna stranica","item":"https:\/\/otpor.media\/"},{"@type":"ListItem","position":2,"name":"Nije klini\u010dko ispitivanje, nego lije\u010denje: Ruski institut kre\u0107e s prvom primjenom cjepiva protiv raka"}]},{"@type":"WebSite","@id":"https:\/\/otpor.media\/#website","url":"https:\/\/otpor.media\/","name":"OTPOR.Media","description":"Povratak u realnost","publisher":{"@id":"https:\/\/otpor.media\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/otpor.media\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"hr"},{"@type":"Organization","@id":"https:\/\/otpor.media\/#organization","name":"OTPOR.Media","url":"https:\/\/otpor.media\/","logo":{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/otpor.media\/#\/schema\/logo\/image\/","url":"https:\/\/otpor.media\/wp-content\/uploads\/2020\/01\/logo-OTPOR-2026-1024x683.png","contentUrl":"https:\/\/otpor.media\/wp-content\/uploads\/2020\/01\/logo-OTPOR-2026-1024x683.png","width":1024,"height":683,"caption":"OTPOR.Media"},"image":{"@id":"https:\/\/otpor.media\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/otpor.media","https:\/\/www.youtube.com\/@milimarusic1","https:\/\/www.tiktok.com\/@otpor.media"],"email":"otpormedia@gmail.com"},{"@type":"Person","@id":"https:\/\/otpor.media\/#\/schema\/person\/a274232a44e6bceb3b5681f0fe2474ab","name":"otpormedia","image":{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/secure.gravatar.com\/avatar\/45a679ede28b0f3d33af0c73504f366135a2d7b98929bf9c49d873909aaac267?s=96&d=wavatar&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/45a679ede28b0f3d33af0c73504f366135a2d7b98929bf9c49d873909aaac267?s=96&d=wavatar&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/45a679ede28b0f3d33af0c73504f366135a2d7b98929bf9c49d873909aaac267?s=96&d=wavatar&r=g","caption":"otpormedia"},"sameAs":["https:\/\/test.otpor.media"],"url":"https:\/\/otpor.media\/?author=1"}]}},"jetpack_sharing_enabled":true,"jetpack-related-posts":[],"jetpack_featured_media_url":"https:\/\/otpor.media\/wp-content\/uploads\/2024\/07\/covid_cijepljenje_18622.jpeg","_links":{"self":[{"href":"https:\/\/otpor.media\/index.php?rest_route=\/wp\/v2\/posts\/49239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/otpor.media\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/otpor.media\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/otpor.media\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/otpor.media\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49239"}],"version-history":[{"count":1,"href":"https:\/\/otpor.media\/index.php?rest_route=\/wp\/v2\/posts\/49239\/revisions"}],"predecessor-version":[{"id":49240,"href":"https:\/\/otpor.media\/index.php?rest_route=\/wp\/v2\/posts\/49239\/revisions\/49240"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/otpor.media\/index.php?rest_route=\/wp\/v2\/media\/11641"}],"wp:attachment":[{"href":"https:\/\/otpor.media\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/otpor.media\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/otpor.media\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}